[
 {
  "trial": "T027",
  "source": "fulltext",
  "arms": {
   "Intervention group": {
    "randomized": null,
    "analysed": "67"
   },
   "Control group": {
    "randomized": null,
    "analysed": "67"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Intervention group": {
      "mean": "13.78",
      "sd": "3.87",
      "n": null
     },
     "Control group": {
      "mean": "13.79",
      "sd": "4.78",
      "n": null
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 14,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Intervention group": {
      "mean": "11.82",
      "sd": "3.41",
      "n": null
     },
     "Control group": {
      "mean": "14.34",
      "sd": "4.29",
      "n": null
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 28,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Intervention group": {
      "mean": "10.84",
      "sd": "3.48",
      "n": null
     },
     "Control group": {
      "mean": "13.09",
      "sd": "3.79",
      "n": null
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Table 2 names its columns by drug: 'Ketamine-Nesdonal group' (ketamine 0.5 mg/kg with Nesdonal at induction) = Intervention group, 'Nesdonal group' (Nesdonal alone) = Control group, printed Nesdonal first; the Results text's within-group trends (ketamine group falling at 2 and 4 weeks, Nesdonal group rising at 2 weeks) and Table 2's Greenhouse-Geisser F (4.68 Nesdonal, 52.52 Ketamine-Nesdonal) agree with these labels. Times: 'before caesarian section' = day -1, 'two weeks after' = 14, 'four weeks after' = 28 (EPDS by phone). Analysed: the Results say 'In total, 67 participants were studied in both groups'; Table 1's counts sum to 67 in each column (history of depression 15 + 52 and 10 + 57; education 5 + 17 + 45 and 4 + 25 + 38; the control's wanted/unwanted pregnancy row sums to 66), so 67 is per group, not in all. No number randomized per arm (the CONSORT figure's contents are not in the text; 35 per group were planned) and no n per time point. Labelling inconsistency: the Results text gives mean age 27.4±4.09 to the Nesdonal group, while Table 1 gives 27.40 (4.09) to the Intervention group; Table 2 labels its columns by drug, so the outcomes are unaffected. No adverse events, blinding check, enrollment dates or registration are reported.",
  "reason": "The coders differed only on analysed. The Results print 'In total, 67 participants were studied in both groups', and Table 1's frequencies with their percentages sum to 67 in each column (for example 15 (22.4) + 52 (77.6) and 10 (14.9) + 57 (85.1)), which rules out 67 in all; so the printed 67 is the number per group and is kept as analysed for both arms, as coder A had it. Randomized stays blank, since no per-arm number randomized is printed. The depression values were checked against Table 2 and are unchanged."
 },
 {
  "trial": "T037",
  "source": "registry",
  "arms": {
   "Low-Dose Ketamine (LDK) Treatment Group": {
    "randomized": "1",
    "analysed": "0"
   },
   "Control Group": {
    "randomized": "0",
    "analysed": "0"
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [
   {
    "window": "overall",
    "time": "registry adverse-event time frame: 1 day",
    "location": "Adverse events (1 day)",
    "values": {
     "Low-Dose Ketamine (LDK) Treatment Group": {
      "any_ae": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "NCT05229653",
   "date": null
  },
  "note": "ClinicalTrials.gov posted results. Participant flow: STARTED 1 (LDK) and 0 (Control); COMPLETED 0 and 0; NOT COMPLETED 1 and 0; randomized records the STARTED counts. Every outcome (pelvic pain VAS, GAD-7 and MADRS at baseline and POD 1, 27, 55 and 83; EHP-30; change in opioid use) lists Analysed 0 in both arms and no values, so there are no depression or pain entries. Adverse events (time frame 1 day): LDK serious 0/1, other 0/1; Control serious 0/0, other 0/0. The registry's serious and other (non-serious) tables together hold every adverse event, and with one participant at risk no event could fall under a reporting threshold, so any_ae '0' for LDK is the registry's printed zero; the control arm had no one at risk and has no adverse-event values. No enrollment dates or registration date are given.",
  "reason": "The coders differed on whether to record the registry's adverse events. The registry prints serious 0/1 and other 0/1 for the ketamine arm; its serious and other tables together cover every adverse event, so the source reports that the one participant at risk had no adverse event, and any_ae '0' (window overall, the registry's 1-day time frame) is kept, as coder A had it. The control arm had no one at risk and gets no values. The rest (1 and 0 started, 0 analysed, no outcome values) was confirmed in the registry text."
 },
 {
  "trial": "T046",
  "source": "library",
  "arms": {
   "Placebo group": {
    "randomized": "100",
    "analysed": "97"
   },
   "Low-dose esketamine group (1 mg/kg PCIA)": {
    "randomized": "100",
    "analysed": "99"
   },
   "High-dose esketamine group (2 mg/kg PCIA)": {
    "randomized": "100",
    "analysed": "99"
   }
  },
  "depression": [
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": -1,
    "form": "median_iqr",
    "location": "Results 3.3, text",
    "values": {
     "Placebo group": {
      "median": "12.0",
      "q1": "11.0",
      "q3": "13.0",
      "n": null
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "12.0",
      "q1": "10.0",
      "q3": "13.0",
      "n": null
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "11.0",
      "q1": "10.0",
      "q3": "13.0",
      "n": null
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 7,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS > 9 (PDS)",
    "values": {
     "Placebo group": {
      "events": "29",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "events": "11",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "events": "7",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 7,
    "form": "count",
    "location": "Table 2",
    "definition": "remission: EPDS < 6 (from an antenatal EPDS > 9); events are remitters, not participants with depression",
    "values": {
     "Placebo group": {
      "events": "34",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "events": "56",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "events": "68",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 7,
    "form": "median_iqr",
    "location": "Results 3.3, text (Fig. 2)",
    "values": {
     "Placebo group": {
      "median": "7.0",
      "q1": "4.0",
      "q3": "10.0",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "5.0",
      "q1": "2.0",
      "q3": "7.0",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "4.0",
      "q1": "1.0",
      "q3": "7.0",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 7,
    "form": "change_median_iqr",
    "location": "Results 3.3, text (Fig. 3)",
    "values": {
     "Placebo group": {
      "median": "-5.0",
      "q1": "-9.0",
      "q3": "-2.0",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "-7.0",
      "q1": "-10.0",
      "q3": "-4.0",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "-8.0",
      "q1": "-10.0",
      "q3": "-5.0",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 42,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS > 9 (PDS)",
    "values": {
     "Placebo group": {
      "events": "27",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "events": "14",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "events": "9",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 42,
    "form": "count",
    "location": "Table 2",
    "definition": "remission: EPDS < 6 (from an antenatal EPDS > 9); events are remitters, not participants with depression",
    "values": {
     "Placebo group": {
      "events": "39",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "events": "58",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "events": "68",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 42,
    "form": "median_iqr",
    "location": "Results 3.3, text (Fig. 2)",
    "values": {
     "Placebo group": {
      "median": "6.0",
      "q1": "3.0",
      "q3": "10.0",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "5.0",
      "q1": "2.0",
      "q3": "8.0",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "3.0",
      "q1": "1.0",
      "q3": "7.0",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 42,
    "form": "change_median_iqr",
    "location": "Results 3.3, text (Fig. 3)",
    "values": {
     "Placebo group": {
      "median": "-6.0",
      "q1": "-9.0",
      "q3": "-2.5",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "-7.00",
      "q1": "-10.0",
      "q3": "-4.0",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "-8.0",
      "q1": "-10.0",
      "q3": "-5.0",
      "n": "99"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS postoperative pain",
    "day": 1,
    "form": "median_iqr",
    "location": "Results 3.3, text (at rest, 24 h; Fig. 4a)",
    "values": {
     "Placebo group": {
      "median": "2.0",
      "q1": "2.0",
      "q3": "3.0",
      "n": null
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": null
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "3.0",
      "n": null
     }
    }
   },
   {
    "measure": "NRS postoperative pain",
    "day": 2,
    "form": "median_iqr",
    "location": "Results 3.3, text (at rest, 48 h; Fig. 4a)",
    "values": {
     "Placebo group": {
      "median": "2.0",
      "q1": "2.0",
      "q3": "2.0",
      "n": null
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "1.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": null
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "1.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": null
     }
    }
   },
   {
    "measure": "NRS score on movement",
    "day": 2,
    "form": "median_iqr",
    "location": "Results 3.3, text (on movement, 48 h; Fig. 4b)",
    "values": {
     "Placebo group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": null
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": null
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 3, Intraoperative events",
    "values": {
     "Placebo group": {
      "hallucination": "0",
      "dissociation": "0",
      "visual": "0",
      "dizziness": "2"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "hallucination": "2",
      "dissociation": "3",
      "visual": "1",
      "dizziness": "11"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "hallucination": "1",
      "dissociation": "1",
      "visual": "2",
      "dizziness": "14"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 3, Postoperative events",
    "values": {
     "Placebo group": {
      "dizziness": "3"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "dizziness": "4"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "dizziness": "3"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-12",
   "end": "2022-01",
   "location": "Methods 2.1 (study conducted from December 2020 to January 2022); the Results give no dates"
  },
  "registration": {
   "number": "ChiCTR-ROC-2000039069",
   "date": null
  },
  "note": "Tables print the esketamine columns first ('PCIA esketamine 2 mg kg−1' = High-dose, '1 mg kg−1' = Low-dose), then Placebo. Randomized 100 per arm (Results 3.1: 300 randomized, 295 completed); analysed 99 (2 mg), 99 (1 mg), 97 (placebo), the column n of Tables 1-3 and the abstract. Counts from Table 2: PDS (EPDS > 9, the primary outcome) and remission (EPDS < 6, from an antenatal EPDS > 9); the remission entries count remitters, not participants with depression, as their definition says. Table 2's percentages use its column n at both days (29/97 = 29.9 %, 11/99 = 11.1 %), so that n is the number assessed at days 7 and 42 and is given for the EPDS medians and changes at those days; the baseline n is not printed. Table 2 also prints ORs vs placebo for both counts (not entered, since the arm counts are given). EPDS medians (IQR) and median (IQR) changes from baseline ('antenatal day 1', coded day -1) are from the Results 3.3 text; Figs 2 and 3 print no values. Day 7 medians are printed pairwise (placebo 7.0 [4.0, 10.0] vs low 5.0 [2.0, 7.0], and vs high 4.0 [1.0, 7.0]); day 42 likewise (high 3.0 [1.0, 7.0] vs placebo 6.0 [3.0, 10.0], and vs low 5.0 [2.0, 8.0]). The text once calls the change a 'mean change' but prints median (IQR). Minus signs printed as '− ' are written '-'; the low-dose day 42 change is printed '− 7.00'. NRS: at-rest medians are printed for 6, 24 and 48 h (6 h is outside the day windows; the low-dose 48 h value is printed '1.0 [1.0, 2.0;'); on movement only the 48 h values are printed (24 h: 'no significant differences'), entered under the source's name since the design lists one NRS measure. Adverse events from Table 3: nystagmus = visual; intraoperative dysphoria (2 mg 1, 1 mg 1, placebo 0), muscular hypertonia, nausea, vomit, shiver, hypertension and cold sweat are not codebook categories; the text's 'several mild psychiatric adverse effects' gives no count. CADSS was planned at 40 min, but only Table 3's dissociation counts are reported. Enrollment is from Methods 2.1 (the Results give no dates). Blinding: the Limitations say participants were not asked which group they thought they were in.",
  "reason": "The coders differed only on n for the EPDS medians and median changes at days 7 and 42. Table 2 prints the column n (99, 99, 97) and computes its day 7 and day 42 percentages on them, so the number assessed at those days is given, and coder A's n are kept; the baseline n stays blank. I also added Table 2's remission counts (EPDS < 6) at days 7 and 42 as count entries whose definition says they count remitters; both coders had left them in the note only. All other values were checked against the Results text and Tables 2 and 3."
 },
 {
  "trial": "T090",
  "source": "fulltext",
  "arms": {
   "Control group (group C)": {
    "randomized": "30",
    "analysed": null
   },
   "Esketamine group S1": {
    "randomized": "30",
    "analysed": null
   },
   "Esketamine group S2": {
    "randomized": "30",
    "analysed": null
   },
   "Esketamine group S3": {
    "randomized": "30",
    "analysed": null
   }
  },
  "depression": [
   {
    "measure": "HADS depression subscale",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 4, Preoperative",
    "values": {
     "Control group (group C)": {
      "mean": "3.70",
      "sd": "1.57",
      "n": null
     },
     "Esketamine group S1": {
      "mean": "3.23",
      "sd": "1.45",
      "n": null
     },
     "Esketamine group S2": {
      "mean": "3.10",
      "sd": "1.57",
      "n": null
     },
     "Esketamine group S3": {
      "mean": "3.62",
      "sd": "1.32",
      "n": null
     }
    }
   },
   {
    "measure": "HADS depression subscale",
    "day": null,
    "form": "mean_sd",
    "location": "Table 4, rows under 'Postoperativ' (time not stated)",
    "values": {
     "Control group (group C)": {
      "mean": "3.42",
      "sd": "1.30",
      "n": null
     },
     "Esketamine group S1": {
      "mean": "2.75",
      "sd": "1.35",
      "n": null
     },
     "Esketamine group S2": {
      "mean": "3.13",
      "sd": "1.35",
      "n": null
     },
     "Esketamine group S3": {
      "mean": "3.33",
      "sd": "1.33",
      "n": null
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest (3, 6, 12, 24, 48 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3, 24h (static state)",
    "values": {
     "Control group (group C)": {
      "median": "1",
      "q1": "1",
      "q3": "1.25",
      "n": null
     },
     "Esketamine group S1": {
      "median": "1",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S2": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Esketamine group S3": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     }
    }
   },
   {
    "measure": "NRS at rest (3, 6, 12, 24, 48 h)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3, 48h (static state)",
    "values": {
     "Control group (group C)": {
      "median": "1",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Esketamine group S1": {
      "median": "1",
      "q1": "1",
      "q3": "1",
      "n": null
     },
     "Esketamine group S2": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Esketamine group S3": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     }
    }
   },
   {
    "measure": "NRS during exercise (3, 6, 12, 24, 48 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2, 24h (exercise status)",
    "values": {
     "Control group (group C)": {
      "median": "2",
      "q1": "2",
      "q3": "2",
      "n": null
     },
     "Esketamine group S1": {
      "median": "2",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S2": {
      "median": "1",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S3": {
      "median": "1",
      "q1": "1",
      "q3": "1",
      "n": null
     }
    }
   },
   {
    "measure": "NRS during exercise (3, 6, 12, 24, 48 h)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2, 48h (exercise status)",
    "values": {
     "Control group (group C)": {
      "median": "1",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S1": {
      "median": "1",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S2": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Esketamine group S3": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 9",
    "values": {
     "Control group (group C)": {
      "dizziness": "5",
      "visual": "0"
     },
     "Esketamine group S1": {
      "dizziness": "4",
      "visual": "0"
     },
     "Esketamine group S2": {
      "dizziness": "2",
      "visual": "0"
     },
     "Esketamine group S3": {
      "dizziness": "3",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-03",
   "end": "2024-03",
   "location": "Methods (patients included between March 2023 and March 2024); the Results give no dates"
  },
  "registration": {
   "number": "ChiCTR2400090449",
   "date": null
  },
  "note": "Esketamine at induction 0.15 (S1), 0.25 (S2), 0.35 (S3) mg/kg, given until 30 min before the end of surgery; group C saline. 120 randomized, 30 per group (Methods). No analysed numbers are stated; the tables' counts sum to 29 for S2 (for example Table 1 male 6 + female 23; Table 9 'Diplopia No 29(100)') and 30 for the others, so analysed is left blank. HADS-D is Table 4's 'HDAS-D' row (mean ± SD); preoperative = day -1; the time of the postoperative assessment is not stated anywhere (the Methods list HADS among 'postoperative assessments'), so its day is null. NRS is printed as median (Q1, Q3) without n; Table 2 'exercise status' = during exercise, Table 3 'static state' = at rest; superscripts a, b dropped; the 3, 6 and 12 h values fall outside the day windows. Not entered: sufentanil consumption (Table 8, 37.30 ± 1.58, 36.90 ± 2.33, 27.48 ± 1.88, 21.73 ± 1.82 µg; given intermittently during maintenance, no postoperative time) and remedial analgesia (Table 9 yes 10 (33.3), 8 (26.7), 6 (20.7), 0 (0); unstated postoperative period). Adverse events, Table 9 (postoperative): 'Dizzy giddy' yes = dizziness; the Diplopia row prints only 'No 30(100) 30(100) 29(100) 30(100)', that is, no one in any group had diplopia, recorded as visual 0 (the text lists diplopia among the adverse reactions compared). The Nightmare row prints 'yes 30(100) 30(100) 29(100) 30(100)', which would mean every patient had nightmares and is presumably a mislabelled 'No' row; not entered. Nausea and vomiting is not a codebook category. Single-blind; no blinding check.",
  "reason": "The coders differed only on visual. Table 9's Diplopia row prints 'No 30(100) 30(100) 29(100) 30(100)', so the source reports that no patient in any group had diplopia, and the text lists diplopia among the postoperative reactions compared; that is a reported zero, not an omission, so visual '0' is kept in each arm, as coder A had it. The Nightmare row, printed 'yes' at 100 % in every group, is self-contradictory and stays out, as both coders had it. Other values were checked against Tables 2, 3, 4 and 9."
 },
 {
  "trial": "T099",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "102",
    "analysed": "102"
   },
   "Saline group": {
    "randomized": "102",
    "analysed": "102"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "2.5",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 7,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "101"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "100"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "4",
      "n": "102"
     },
     "Saline group": {
      "median": "4",
      "q1": "3",
      "q3": "4",
      "n": "102"
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "NRS after movement",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "3",
      "q3": "4",
      "n": "102"
     },
     "Saline group": {
      "median": "4",
      "q1": "3",
      "q3": "4",
      "n": "102"
     }
    }
   },
   {
    "measure": "NRS after movement",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "time": "within 1 h after surgery",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "dizziness": "25",
      "agitation": "2",
      "hallucination": "0",
      "visual": "0"
     },
     "Saline group": {
      "dizziness": "19",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "1–24 h after surgery",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "dizziness": "14",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     },
     "Saline group": {
      "dizziness": "11",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "24–72 h after surgery",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "dizziness": "9",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     },
     "Saline group": {
      "dizziness": "6",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-05-05",
   "end": "2024-10-31",
   "location": "Methods ('Dates of first and last enrollments were May 5, 2024, and October 31, 2024'); the Results give no dates"
  },
  "registration": {
   "number": "NCT06388824",
   "date": null
  },
  "note": "The source calls the saline arm 'Placebo group' (= design 'Saline group'); tables print it first. Esketamine 0.2 mg/kg once, immediately after the start of surgery. 204 randomized, 102 per group; the intention-to-treat analysis includes all 204. Three women declined the day-7 follow-up: Table 3 marks the day-7 values '(2)h' (placebo) and '(1)h' (esketamine), 'patients with missing data owing to refused assessment', and prints the per-protocol n as 100 (placebo) and 101 (esketamine); missing data were not imputed, so the day-7 HADS-D n is 100 and 101. Other n are the column n (102). HADS-D and NRS are median (IQR); Hodges-Lehmann median differences are also printed (HADS-D 0 (0 to 0) at each day; not entered since arm values are given). NRS at postoperative hour 1 falls outside the day windows. Acetaminophen use over the first three postoperative days (placebo 13 (12.8), esketamine 6 (5.9)) has no day 1 or 2 value, so it is not entered. Adverse events from Table 4, whose 'Postoperative period' has three sub-periods, each entered as postoperative with its time: within 1 h after surgery (which spans emergence from the brief propofol anaesthesia, though the source never calls it emergence), 1–24 h and 24–72 h after surgery. Agitation is Table 4's 'Agitation' row only; delirium (within 1 h: placebo 1 (1.0), esketamine 4 (3.9); 0 later), somnolence and memory impairment are separate rows, not added or mapped; visual = diplopia. No codebook category in the intraoperative period. Text: no serious side effects. Enrollment is from the Methods (the Results give no dates). No blinding check reported.",
  "reason": "Two differences. Window: Table 4 prints 'Within 1 h after surgery' under 'Postoperative period' and never calls it emergence, so those events stay postoperative with their time, as coder A had them. Day-7 HADS-D n: Table 3 flags 2 placebo and 1 esketamine patients missing at day 7 and prints the per-protocol n of 100 and 101, and data were not imputed, so coder A's n of 100 (saline) and 101 (esketamine) are kept rather than blanks. All values were checked against Tables 1, 3 and 4."
 }
]